Estramustine Plus Docetaxel After A Vacation as Second-Line Therapy in Patients with Hormone-Refractory Prostate Cancer Resistant to Docetaxel
What is left for us once we become resistant to docetaxel (DOC) plus prednisone, which is the last FDA approved, standard of care treatment available for advanced hormone refractory prostate cancer? There has been some studies that indicate after a “vacation period” similar to what many of us do with a first line hormone blockade, [...]
